4174.TWO
OBI Pharma, Inc. [4174.TWO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4174.TWO Stock Summary
Top 10 Correlated ETFs
4174.TWO
Top 10 Correlated Stocks
4174.TWO
In the News
4174.TWO Financial details
Company Rating
Sell
Market Cap
14.33B
Income
-1.15B
Revenue
41.55M
Book val./share
16.62
Cash/share
12.15
Dividend
-
Dividend %
-
Employees
260
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-12.34
Forward P/E
-
PEG
2.97
P/S
647.87
P/B
3.54
P/C
4.81
P/FCF
-8.25
Quick Ratio
26.22
Current Ratio
28.39
Debt / Equity
0.13
LT Debt / Equity
0.09
-
-
EPS (TTM)
-5
EPS next Y
-
EPS next Q
-
EPS this Y
-35.32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-5.74%
Revenue last 5Y
116.58%
Revenue Q/Q
60.5%
EPS Q/Q
-0.4%
-
-
-
-
SMA20
-1.61%
SMA50
-8.96%
SMA100
-24.69%
Inst Own
-
Inst Trans
-
ROA
-20%
ROE
-27%
ROC
-0.23%
Gross Margin
-285%
Oper. Margin
-5841%
Profit Margin
-5244%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
59.4-99.3
52W High
-40.91%
52W Low
-0.85%
RSI
33
Rel Volume
1.18
Avg Volume
448.55K
Volume
528.22K
Perf Week
-7.87%
Perf Month
-11.5%
Perf Quarter
-26.42%
Perf Half Y
-27.6%
-
-
-
-
Beta
0.982
-
-
Volatility
1.4%, 1.65%
Prev Close
-3.78%
Price
58.5
Change
-2.99%
4174.TWO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.7 | 0.09 | 0.02 | 0.18 | |
| Net income per share | -7.43 | -7.43 | -8.55 | -8.55 | -5.53 | |
| Operating cash flow per share | -5.4 | -8.02 | -5.3 | -7.29 | -7.22 | |
| Free cash flow per share | -5.67 | -8.95 | -6.52 | -8.64 | -7.69 | |
| Cash per share | 23.5 | 18.55 | 13.21 | 21.49 | 12.15 | |
| Book value per share | 26.35 | 21.08 | 13.51 | 20.85 | 16.62 | |
| Tangible book value per share | 24.2 | 21.85 | 17.28 | 25.9 | 21.63 | |
| Share holders equity per share | 26.35 | 21.08 | 13.51 | 20.85 | 16.62 | |
| Interest debt per share | 0.93 | 1.2 | 1.48 | 1.13 | 2.22 | |
| Market cap | 25.57B | 27.88B | 22.91B | 15.35B | 15.92B | |
| Enterprise value | 21.2B | 24.78B | 20.69B | 10.85B | 15.52B | |
| P/E ratio | -17.76 | -18.71 | -13.34 | -8.08 | -12.57 | |
| Price to sales ratio | 29.32K | 197.91 | 1.22K | 3.26K | 383.14 | |
| POCF ratio | -24.43 | -17.32 | -21.52 | -9.48 | -9.63 | |
| PFCF ratio | -23.28 | -15.53 | -17.49 | -7.99 | -9.04 | |
| P/B Ratio | 5.01 | 6.59 | 8.44 | 3.31 | 4.18 | |
| PTB ratio | 5.01 | 6.59 | 8.44 | 3.31 | 4.18 | |
| EV to sales | 24.31K | 175.9 | 1.1K | 2.3K | 373.55 | |
| Enterprise value over EBITDA | -16.62 | -19.7 | -13.59 | -6.51 | -15.24 | |
| EV to operating cash flow | -20.25 | -15.4 | -19.44 | -6.7 | -9.39 | |
| EV to free cash flow | -19.3 | -13.81 | -15.8 | -5.65 | -8.81 | |
| Earnings yield | -0.06 | -0.05 | -0.07 | -0.12 | -0.08 | |
| Free cash flow yield | -0.04 | -0.06 | -0.06 | -0.13 | -0.11 | |
| Debt to equity | 0.03 | 0.06 | 0.11 | 0.05 | 0.13 | |
| Debt to assets | 0.03 | 0.04 | 0.07 | 0.04 | 0.09 | |
| Net debt to EBITDA | 3.43 | 2.47 | 1.46 | 2.7 | 0.39 | |
| Current ratio | 23.53 | 15.67 | 8.72 | 22.76 | 19.92 | |
| Interest coverage | -532.67 | -356 | -457.73 | -479.47 | -263.3 | |
| Income quality | 0.72 | 1.08 | 0.61 | 0.84 | 1.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.06 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 306.81 | 2.06 | 12.83 | 65.75 | 7.68 | |
| Research and developement to revenue | 1.36K | 9.3 | 77.22 | 376.32 | 40.84 | |
| Intangibles to total assets | 0.09 | 0.08 | 0.09 | 0.06 | 0.01 | |
| Capex to operating cash flow | 0.05 | 0.12 | 0.23 | 0.19 | 0.07 | |
| Capex to revenue | -59.14 | -1.32 | -13.06 | -63.8 | -2.6 | |
| Capex to depreciation | -0.31 | -0.8 | -1.13 | -1.22 | -0.43 | |
| Stock based compensation to revenue | 167.57 | 0.55 | 2.88 | 31.63 | 2.87 | |
| Graham number | 66.38 | 59.36 | 50.99 | 63.34 | 45.46 | |
| ROIC | -0.27 | -0.32 | -0.52 | -0.37 | -0.43 | |
| Return on tangible assets | -0.28 | -0.3 | -0.42 | -0.3 | -0.23 | |
| Graham Net | 21.3 | 16.14 | 10.25 | 19.39 | 9.46 | |
| Working capital | 4.51B | 3.65B | 2.53B | 4.81B | 3B | |
| Tangible asset value | 4.69B | 4.38B | 3.47B | 5.75B | 4.88B | |
| Net current asset value | 4.25B | 3.39B | 2.24B | 4.54B | 2.51B | |
| Invested capital | 0.03 | 0.06 | 0.11 | 0.05 | 0.13 | |
| Average receivables | 19.99M | 29.5M | 21.14M | 25.77M | 29.17M | |
| Average payables | 88.5K | 167K | 341K | 834.5K | 958.5K | |
| Average inventory | 2.1M | 5.78M | 8.46M | 15.77M | 23.95M | |
| Days sales outstanding | 16.73K | 49.27 | 452.44 | 2.19K | 264.14 | |
| Days payables outstanding | 0.29 | 8.86 | 4.32 | 9.31 | 2.45 | |
| Days of inventory on hand | 6.77 | 415.16 | 78.67 | 178.8 | 82.27 | |
| Receivables turnover | 0.02 | 7.41 | 0.81 | 0.17 | 1.38 | |
| Payables turnover | 1.28K | 41.2 | 84.5 | 39.21 | 148.83 | |
| Inventory turnover | 53.89 | 0.88 | 4.64 | 2.04 | 4.44 | |
| ROE | -0.28 | -0.35 | -0.63 | -0.41 | -0.33 | |
| Capex per share | -0.27 | -0.93 | -1.22 | -1.35 | -0.47 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.01 | 0.04 | 0.05 | 0.08 | |
| Net income per share | -2.88 | -1.84 | 1.79 | -2.48 | -2.47 | |
| Operating cash flow per share | -2.34 | -1.65 | -1.75 | -1.95 | -1.86 | |
| Free cash flow per share | -2.41 | -1.72 | -1.93 | -2.05 | -1.99 | |
| Cash per share | 20.83 | 21.91 | 15.4 | 14.18 | 12.15 | |
| Book value per share | 20.22 | 19.36 | 21.28 | 18.89 | 16.62 | |
| Tangible book value per share | 25.11 | 26.37 | 26.21 | 24.03 | 21.62 | |
| Share holders equity per share | 20.22 | 19.36 | 21.28 | 18.89 | 16.62 | |
| Interest debt per share | 1.08 | 0.99 | 0.95 | 2.23 | 2.2 | |
| Market cap | 15.83B | 18.64B | 22.25B | 18.79B | 15.92B | |
| Enterprise value | 11.34B | 14.21B | 19.74B | 17.23B | 15.52B | |
| P/E ratio | -6.01 | -11.05 | 13.6 | -8.27 | -7.03 | |
| Price to sales ratio | 31.23K | 10.44K | 2.25K | 1.64K | 864.32 | |
| POCF ratio | -29.49 | -49.23 | -55.43 | -42.07 | -37.32 | |
| PFCF ratio | -28.7 | -47.32 | -50.36 | -40.03 | -34.9 | |
| P/B Ratio | 3.42 | 4.2 | 4.57 | 4.34 | 4.18 | |
| PTB ratio | 3.42 | 4.2 | 4.57 | 4.34 | 4.18 | |
| EV to sales | 22.36K | 7.95K | 2K | 1.5K | 842.7 | |
| Enterprise value over EBITDA | -18.7 | -39.99 | 49.74 | -30.99 | -30.79 | |
| EV to operating cash flow | -21.12 | -37.53 | -49.18 | -38.6 | -36.39 | |
| EV to free cash flow | -20.55 | -36.07 | -44.68 | -36.72 | -34.03 | |
| Earnings yield | -0.04 | -0.02 | 0.02 | -0.03 | -0.04 | |
| Free cash flow yield | -0.03 | -0.02 | -0.02 | -0.02 | -0.03 | |
| Debt to equity | 0.05 | 0.05 | 0.04 | 0.12 | 0.13 | |
| Debt to assets | 0.04 | 0.03 | 0.03 | 0.08 | 0.09 | |
| Net debt to EBITDA | 7.41 | 12.47 | -6.32 | 2.79 | 0.79 | |
| Current ratio | 22.76 | 36.83 | 34.64 | 28.39 | 19.92 | |
| Interest coverage | -741.67 | -444.24 | 359.52 | -183.65 | -183.47 | |
| Income quality | 0.8 | 0.9 | -1.19 | 0.71 | 0.76 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 152.33 | 41.76 | 8.06 | 7.84 | 4.08 | |
| Research and developement to revenue | 1.09K | 189.46 | 46.08 | 44.14 | 21.58 | |
| Intangibles to total assets | 0.06 | 0.05 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0.03 | 0.04 | 0.1 | 0.05 | 0.07 | |
| Capex to revenue | -29.13 | -8.56 | -4.1 | -1.99 | -1.61 | |
| Capex to depreciation | -0.22 | -0.23 | -0.69 | -0.34 | -0.53 | |
| Stock based compensation to revenue | 57.39 | 17.47 | 3.58 | 3.22 | 0.85 | |
| Graham number | 36.17 | 28.33 | 29.25 | 32.45 | 30.39 | |
| ROIC | -0.13 | -0.09 | 0.06 | -0.11 | -0.1 | |
| Return on tangible assets | -0.11 | -0.07 | 0.06 | -0.09 | -0.1 | |
| Graham Net | 18.8 | 20.26 | 14.11 | 11.58 | 9.46 | |
| Working capital | 4.81B | 5.13B | 3.67B | 3.39B | 3B | |
| Tangible asset value | 5.75B | 6.04B | 6B | 5.43B | 4.88B | |
| Net current asset value | 4.54B | 4.86B | 3.45B | 2.88B | 2.51B | |
| Invested capital | 0.05 | 0.05 | 0.04 | 0.12 | 0.13 | |
| Average receivables | 24.57M | 27M | 27.09M | 30.94M | 31.75M | |
| Average payables | 735.5K | 653K | 2.44M | 4.12M | 2.14M | |
| Average inventory | 22.85M | 22.83M | 24.94M | 25.96M | 25.83M | |
| Days sales outstanding | 5.02K | 1.3K | 259.55 | 262.13 | 146.92 | |
| Days payables outstanding | 11.85 | 0.69 | 14.93 | 9.59 | 2.13 | |
| Days of inventory on hand | 227.62 | 101.43 | 82.82 | 70.28 | 71.53 | |
| Receivables turnover | 0.02 | 0.07 | 0.35 | 0.34 | 0.61 | |
| Payables turnover | 7.59 | 129.72 | 6.03 | 9.38 | 42.21 | |
| Inventory turnover | 0.4 | 0.89 | 1.09 | 1.28 | 1.26 | |
| ROE | -0.14 | -0.1 | 0.08 | -0.13 | -0.15 | |
| Capex per share | -0.06 | -0.07 | -0.18 | -0.1 | -0.13 |
4174.TWO Frequently Asked Questions
What is OBI Pharma, Inc. stock symbol ?
OBI Pharma, Inc. is a TW stock and trading under the symbol 4174.TWO
What is OBI Pharma, Inc. stock quote today ?
OBI Pharma, Inc. stock price is $58.5 today.
Is OBI Pharma, Inc. stock public?
Yes, OBI Pharma, Inc. is a publicly traded company.
Company Profile
- Volume Average 448.55K
- Market Capitalization 14.33B
- Employee 260
- CEO Dr. Heidi Wang Ph.D.
- Headquarters Taipei,TW
- IPO Date 2012-12-12
-
Website
https://www.obipharma.com 
OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898 and OBI-998 drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.
